These findings indicate that elevated serum FGF21 levels may be a protective response against glucose-lipid metabolism disorders in patients and mice with NAFLD/NASH (Table 1). This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.